December
1, 2020
On
December 1, 2020, the ex-Pfizer head of respiratory research Dr. Michael Yeadon
and the lung specialist and former head of the public health department Dr.
Wolfgang Wodarg filed an application with the EMA,
the European Medicine Agency responsible for EU-wide drug approval, for the
immediate suspension of all SARS CoV 2 vaccine studies, in particular the BioNtech/Pfizer
study on BNT162b (EudraCT number 2020-002641-42).
Dr.
Wodarg and Dr. Yeadon demand that the studies – for the protection of the life
and health of the volunteers – should not be continued until a study design is
available that is suitable to address the significant safety concerns expressed
by an increasing number of renowned scientists against the vaccine and the
study design.
On
the one hand, the petitioners demand that, due to the known lack of accuracy of
the PCR test in a serious study, a so-called Sanger sequencing must be used.
This is the only way to make reliable statements on the effectiveness of a
vaccine against Covid-19. On the basis of the many different PCR tests of
highly varying quality, neither the risk of disease nor a possible vaccine
benefit can be determined with the necessary certainty, which is why testing
the vaccine on humans is unethical per se.
Furthermore,
they demand that it must be excluded, e.g. by means of animal experiments, that
risks already known from previous studies, which partly originate from the
nature of the corona viruses, can be realized. The concerns are directed in
particular to the following points:
·
The formation of so-called “non-neutralizing
antibodies” can lead to an exaggerated immune reaction, especially when the
test person is confronted with the real, “wild” virus after vaccination. This
so-called antibody-dependent amplification, ADE, has long been known from
experiments with corona vaccines in cats, for example. In the course of these
studies all cats that initially tolerated the vaccination well died after
catching the wild virus.
·
The vaccinations are expected to produce antibodies
against spike proteins of SARS-CoV-2. However, spike proteins also contain
syncytin-homologous proteins, which are essential for the formation of the
placenta in mammals such as humans. It must be absolutely ruled out that a
vaccine against SARS-CoV-2 could trigger an immune reaction against syncytin-1,
as otherwise infertility of indefinite duration could result in vaccinated
women.
·
The mRNA vaccines from BioNTech/Pfizer contain
polyethylene glycol (PEG). 70% of people develop antibodies against this
substance – this means that many people can develop allergic, potentially fatal
reactions to the vaccination.
·
The much too short duration of the study does not
allow a realistic estimation of the late effects. As in the narcolepsy cases
after the swine flu vaccination, millions of healthy people would be exposed to
an unacceptable risk if an emergency approval were to be granted and the
possibility of observing the late effects of the vaccination were to follow.
Nevertheless, BioNTech/Pfizer apparently submitted an application for emergency
approval on December 1, 2020.
CALL
FOR HELP: Dr. Wodarg and Dr. Yeadon ask as many EU
citizens as possible to co-sign their petition by sending the e-mail prepared here to the EMA.
Addendum:
Due to partial overload of the server, here is the content of the e-mail and
the contact addresses for later self-sending:
To:
press@ema.europa.eu; petitionEMA@corona-ausschuss.com
Subject:
Co-signing the petition of Dr. Wodarg, Germany, and Dr. Yeadon, UK (submitted
on 1-Dec-2020)
Dear Sir or Madam,
I am hereby co-signing the petition of Dr. Wodarg and Dr. Yeadon to support their urgent request to stay the Phase III clinical trial(s) of BNT162b (EudraCT Number 2020-002641-42) and other clinical trials. The full text of the petition of Dr. Wodarg and Dr. Yeadon can be found here:
I hereby respectfully request that EMA act on the petition of Dr. Wodarg and Dr. Yeadon immediately. Regards
/https://www.niagarafallsreview.ca/content/dam/thestar/news/canada/2021/09/25/huawei-executive-meng-wanzhou-receives-warm-welcome-upon-return-to-china/_1_meng_wanzhou_2.jpg)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.